Medpace (NASDAQ:MEDP) Stock: Insider August Troendle Sells 21,966 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,966 shares of Medpace stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares in the company, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Price Performance

Shares of MEDP stock traded down $26.10 during trading hours on Thursday, hitting $598.08. The stock had a trading volume of 232,765 shares, compared to its average volume of 330,847. The firm has a market capitalization of $16.69 billion, a PE ratio of 35.06, a PEG ratio of 2.78 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock’s 50 day moving average is $600.14 and its 200 day moving average is $519.59.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on MEDP shares. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Truist Financial boosted their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average target price of $602.27.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new position in Medpace during the 2nd quarter worth $27,000. Jones Financial Companies Lllp purchased a new stake in shares of Medpace in the second quarter valued at about $30,000. Allied Private Wealth LLC purchased a new stake in shares of Medpace in the second quarter valued at about $31,000. Kilter Group LLC acquired a new position in shares of Medpace during the second quarter worth about $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Medpace during the second quarter worth about $34,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.